Physician profile
Weijie V Lin
NPI 1801356092
$9,901.70
in general payments reported to CMS, 2019-2025
7 companies · $3,574 in 2025
The $3,574 reported for 2025 was more than what 90% of Cornea and External Diseases Specialist providers received nationally (typical 2025 total: $477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $333 · 2024: $5,995 · 2025: $3,574.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,250 · Food and Beverage: $1,652.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,250.00 |
| Food and Beverage | $1,651.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $8,501.38 | 2023-2025 | Ce-Marked Kxla System, Kxl System, Idosetr |
| Alcon Vision LLC | $405.74 | 2023-2025 | Clareon, Tryptyr |
| Dompe US, INC. | $394.69 | 2024-2025 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $392.55 | 2024-2025 | Xdemvy |
| Biotissue Holdings INC. | $134.89 | 2024 | |
| Bausch & Lomb Americas INC. | $40.97 | 2024-2025 | Miebo, Xiidra, Xipere |
| Oyster Point Pharma, INC. | $31.48 | 2024 | Tyrvaya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Weijie Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.